Centre Leon Berard — Sponsor Intelligence | 27 EU Trials

Filter these 27 trials by condition, phase, country and more.

Open in Search →

27 Registered trials

17 Recruiting

10 Completed trials

13 Countries active

44 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 4 Phase II/III: 1 Phase II: 14 Phase I/II: 8

100%

10 of 10 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Ependymoma 1 Soft tissue sarcoma 1 Sarcoma 1 Metastatic renal cell carcinoma 1 Gastric cancer 1

Top IMPs

ATEZOLIZUMAB 3 CISPLATIN 2 DURVALUMAB 2 NIVOLUMAB 2 PEMBROLIZUMAB 2 ANASTROZOLE 1 BALSTILIMAB 1 BOTENSILIMAB 1 COBIMETINIB 1 CYCLOPHOSPHAMIDE 1 DOSTARLIMAB 1 ETOPOSIDE 1

All trials

27 total

COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vul… Pending

2025-524759-29-00 Phase I/II 1 country IMIQUIMOD; NIVOLUMAB
Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combin… Recruiting

2023-506291-28-00 Phase III 1 country BALSTILIMAB; BOTENSILIMAB; FLUOROURACIL; NIVOLUMAB; OXALIPLATIN
TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II t… Recruiting

2023-510568-11-00 Phase I/II 1 country TARLATAMAB
LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing st… Recruiting

2022-501315-13-00 Phase III 3 countries
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting

2023-506590-35-00 Phase II 1 country DURVALUMAB
Study aiming to assess the clinical impact of dostarlimab on occurrence of second primary cancer in patients with cured primary cancer Recruiting

2022-501316-34-00 Phase II 1 country DOSTARLIMAB
EDEN : Etude de désescalade thérapeutique et d'évaluation du marqueur miRNA M371 pour les séminomes de stade IIa/IIb < 3 cm Recruiting

2024-514636-25-00 Phase II 1 country CISPLATIN
Study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma … Recruiting

2024-513986-38-00 Phase II 1 country PEMBROLIZUMAB
Study evaluating the clinical impact of HDM201 + Pazopanib in patients with P53 wild-type advanced/ metastatic soft tissue sarcomas. Recruiting

2024-510706-86-00 Phase I/II 1 country
A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib … Recruiting

2022-503068-34-00 Phase II 1 country ATEZOLIZUMAB
Study evaluating the interest of imatinib treatment maintenance or interruption after at least 10 years of treatment in patients with locall… Recruiting

2024-512631-77-00 Phase II 1 country
Clinical trial evaluating the value of treatment with therapy specifically targeting the molecular alterations identified in the tumor of pa… Recruiting

2023-510567-35-00 Phase II 1 country SIREMADLIN
A multicentre trial evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advance… Recruiting

2024-510712-75-00 Phase I/II 1 country ATEZOLIZUMAB; COBIMETINIB
Study describing the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bone sarcomas Recruiting

2024-514637-37-00 Phase III 1 country REGORAFENIB
Trial that evaluates the interest of interruption versus maintaining the treatment of aromatase inhibitors in patients with metastatic low g… Recruiting

2024-512629-97-00 Phase II 1 country ANASTROZOLE; EXEMESTANE
VICTORIA (hormone receptor postiVe endometrIal Carcinoma treated by dual mTORC1/mTORC2 Inhibitor and Anastrozole):A Multicentric, randomized… Recruiting

2024-516725-31-00 Phase I/II 1 country
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym… Recruiting

2024-512222-28-00 Phase II/III 13 countries CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; METHOTREXATE; SODIUM VALPROATE; VINCRIST…
MOST Plus (My Own Specific Treatment) - A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of… Recruiting

2023-510566-27-00 Phase II 1 country DURVALUMAB; NILOTINIB; OLAPARIB; TREMELIMUMAB
MSI/dMMR tumors in perioperative setting Ended

2024-518127-30-00 Phase II 1 country PEMBROLIZUMAB
A clinical trial aiming to assess the effect of an immunotherapy for the treatment of soft tissue sarcomas treated by radiotherapy Ended

2024-510713-15-00 Phase II 1 country ATEZOLIZUMAB
AML-NET : Acute Myeloid Leukemia treated with with NETrin Abs in combination with [AZACITIDINE + VENETOCLAX] Ended

2023-503408-10-00 Phase I/II 1 country
Study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer Ended

2022-502440-12-00 Phase I/II 1 country
RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in pa… Ended

2024-513982-38-00 Phase III 1 country
Study that evaluating the efficacy of lenvatinib in patients with locally advanced GIST after failure of imatinib and sunitinib Ended

2024-513984-22-00 Phase II 1 country LENVATINIB

Showing 1–24 of 27 trials

← All sponsors A–Z